1 Department of Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
2 Key Clinical Laboratory of Henan province, Zhengzhou, Henan, People's Republic of China.
Technol Cancer Res Treat. 2017 Aug;16(4):435-439. doi: 10.1177/1533034616666644. Epub 2016 Aug 24.
Serum markers with increased sensitivity and specificity for endometrial cancer are required. To date, no good marker has met this standard. The aims of our study were to evaluate the utility of tumor markers HE4, CA125, CA724, and CA19-9 as potential markers in patients diagnosed with endometrial cancer.
Blood samples from 105 patients with endometrial cancer and 87 healthy women were analyzed by Roche electrochemiluminescent immunoassay, and serum values were measured for the following biomarkers: HE4, CA125, CA724, and CA19-9.
Serum HE4, CA125, CA724, and CA19-9 concentrations were significantly higher in patients with endometrial cancer, compared with controls ( P < .001). In the receiver operating characteristic analysis, the area under the curve value for combination of HE4, CA125, CA724, and CA19-9 was 82.1% (95% confidence interval: 75.3%-86.2%), the maximum area of the test groups. For all stages of patients with endometrial cancer, HE4 had higher sensitivity (58%), positive predictive value (60%), and negative predictive value (67%) than any other single tumor marker, and in the combination of HE4, CA125, CA724, and CA19-9, the sensitivity and positive predictive values reached 59.1% and 88%, respectively. Meanwhile, the receiver operating characteristic area under the curve of the combination of the 4 markers was significantly increased than any other group, either in stage I or in stage II to IV cases. HE4 and CA125 both correlate with advanced age; in addition, HE4 was related to pathology subtypes and positive adnexal involvement, CA125 was related to International Federation of Gynecology and Obstetrics stage, CA19-9 was related to International Federation of Gynecology and Obstetrics stage, and CA724 was correlated with positive lymph node.
Combination of HE4, CA125, CA724, and CA19-9 has the highest value in diagnosing endometrial cancer, and they can be a useful tissue immune marker for patients with endometrial cancer.
需要具有更高灵敏度和特异性的血清标志物来诊断子宫内膜癌。迄今为止，尚无良好的标志物能够满足这一标准。本研究的目的是评估肿瘤标志物 HE4、CA125、CA724 和 CA19-9 作为诊断子宫内膜癌患者潜在标志物的效用。
采用罗氏电化学发光免疫分析法检测 105 例子宫内膜癌患者和 87 例健康女性的血样，并检测以下生物标志物的血清值：HE4、CA125、CA724 和 CA19-9。
与对照组相比，子宫内膜癌患者的血清 HE4、CA125、CA724 和 CA19-9 浓度显著升高（P＜0.001）。在受试者工作特征分析中，HE4、CA125、CA724 和 CA19-9 联合检测的曲线下面积值为 82.1%（95%置信区间：75.3%-86.2%），为检测组的最大面积。对于所有分期的子宫内膜癌患者，HE4 的敏感性（58%）、阳性预测值（60%）和阴性预测值（67%）均高于任何其他单一肿瘤标志物，在 HE4、CA125、CA724 和 CA19-9 的联合检测中，敏感性和阳性预测值分别达到 59.1%和 88%。同时，在 I 期或 II 期至 IV 期患者中，4 种标志物联合检测的受试者工作特征曲线下面积均显著高于其他任何一组。HE4 和 CA125 均与高龄相关；此外，HE4 与病理亚型和附件阳性受累相关，CA125 与国际妇产科联合会分期相关，CA19-9 与国际妇产科联合会分期相关，CA724 与阳性淋巴结相关。
HE4、CA125、CA724 和 CA19-9 的联合检测在诊断子宫内膜癌方面具有最高的价值，它们可以作为子宫内膜癌患者的一种有用的组织免疫标志物。
